Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Napp Gets Authorization for REZZAYO® in Great Britain for Invasive Candidiasis Treatment
Details : Rezzayo (rezafungin) is a novel once-weekly echinocandin, a 1,3-beta-glucan synthase inhibitor. It is approved for the treatment of invasive candidiasis.
Brand Name : Rezzayo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 02, 2024
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The European Commission approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which was stopped early based on the achievement of a pre-specified efficacy c...
Brand Name : Invokana
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 02, 2020
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Positive opinion is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which was stopped early based on a conclusive signal of efficacy in the prevention of the prim...
Brand Name : Invokana
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 29, 2020
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?